Midnight Trader - Night Vision for the Investment Community
Home Login  Contact Us
 

The After-Hours Trading Community

Current Articles | RSS Feed RSS Feed

ImClone Surging in Pre-Market Trading, Erbitux Gaining Cred

Posted by Brooks McFeely on Fri, Apr 18, 2008 @ 08:19
Digg digg it | Reddit reddit | del.icio.us del.icio.us | StumbleUpon StumbleUpon 
ImClone (IMCL) is among the most actively traded stocks in pre-market action, generating upside after Morgan Stanley suggested ImClone's Erbitux cancer treatment could pose stiff competition against Genentech's Avastin lung cancer treatment.

Also adding to ImClone's upside this morning is a report from Genentech finding that while its Avastin improved progression free survival in patients with non-small cell lung cancer it did not prolong their overall survival.

Genentech shares are down 2% at 70.31 in pre-market trade, but the top morning bid stands at 70.53, an indication the stock may see some near term bounce.

Tags: ,

COMMENTS

Currently, there are no comments. Be the first to post one!
Post Comment
Name
 *
Email
 *
Website (optional)
Comment
 *

Allowed tags: <a> link, <b> bold, <i> italics

Receive email when someone replies.

FREE EARNINGS TRADING SEMINAR

Learn to how to trade earnings events in 30 minutes!

NEXT FREE EVENT
07/22/2008 4:30 PM EST
REGISTER HERE

 

Download Whitepaper on After-Hours Trading

Subscribe via Email

Your email:

Midnight Trader's Real-Time Services

Add to Technorati Favorites

Posts by Month

Browse By tag

   
Partners Press Disclaimer Copyright Privacy Help

MidnightTrader, Inc. is the leading provider of after-hours and pre-market stock trading news, charts, quotes, alerts, personal finance, and stock market information available. MidnightTrader journalists are subject to the MidnightTrader Editorial Handbook which requires fair presentation and disclosure of relevant interests.

MidnightTrader 2008, All Rights Reserved